Rising Biosciences (Rising Biosciences) Purchase Of Investment : $ Mil (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Purchase Of Investment?

Rising Biosciences's purchase of investment for the three months ended in . 20 was $0.00 Mil. It means Rising Biosciences spent $0.00 Mil on purchasing investments.

Compared with last quarter ($0.00 Mil in . 20 ), Rising Biosciences spent the same money on purchasing investments in . 20 ($0.00 Mil).

Rising Biosciences Purchase Of Investment Historical Data

The historical data trend for Rising Biosciences's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Purchase Of Investment Chart

Rising Biosciences Annual Data

Trend

Purchase Of Investment

Rising Biosciences Quarterly Data

Purchase Of Investment

Rising Biosciences Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Rising Biosciences Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Purchase Of Investment

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.